Whitehawk Therapeutics, Inc.

WHWK

Healthcare Biotechnology

Whitehawk Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.1 million, down 72.5% from fiscal 2024.

Revenue
+33.5%
EPS
+73.7%
Free cash flow
+72.6%

Quarter to June 2026, against a year earlier

3.13 0.11 +3.64%
Market cap
$178.4M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
1.3×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
17.38 11.36 10.26 16.76
Net Debt/EBITDA
10.29 5.16 5.67 8.03
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.18) (0.32) (0.28) (0.22)
Book value per Share
2.21 1.68 2.20 2.27
Free Cash Flow
(14.53) (22.21) (17.23) (15.38)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026